XNW28012
Not Specified (Oncology)
Phase 3Active
Key Facts
About Evopoint Biosciences
Evopoint Biosciences is a rapidly emerging, privately held biopharmaceutical company with a robust pipeline of over 17 programs, including 7 in clinical stages. Its strategy is built on three proprietary technology platforms—Small Molecule, Novel Antibody, and Targeted Protein Degradation—targeting high-value areas in oncology and anti-infectives. The company has demonstrated significant validation through over $2 billion in landmark licensing deals with major pharmaceutical partners and has advanced multiple candidates to Phase III or NDA stages, supported by regulatory designations from the FDA and NMPA. Evopoint is actively building an integrated, end-to-end ecosystem from discovery to global commercialization.
View full company profileTherapeutic Areas
Other Not Specified (Oncology) Drugs
| Drug | Company | Phase |
|---|---|---|
| IMGS-203 | ImmunoGenesis | Pre-clinical |
| Anti-TM4SF4 Antibody | Algok Bio | Preclinical |
| Oncology 1 | Actipulse Neuroscience | Pre-clinical |
| SynKIR™-310 | Verismo Therapeutics | Phase 1 |
| AUR112 | Aurigene Oncology | Phase 1 |
| B7H3 Antibody-Drug Conjugate | Ellipses Pharma | Clinical |
| BC3448 | BioCity Biopharma | Phase 1 |
| BC2027 | BioCity Biopharma | Phase 1 |